2019 Year in Review: Waldenstrom Macroglobulinemia

Results from the phase 3 Myeloma XI trial bolster earlier evidence that maintenance therapy with len

Oprozomib Found Active in Multiple Myeloma, Waldenström Macroglobulinemia

More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.

Researchers found that doubling in KIM-1 plasma concentrations were associated with an increased ris

Rituximab Maintenance Therapy in Waldenström Macroglobulinemia: Yay or Nay?

A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.

MGUS may progress to multiple myeloma, AL amyloidosis, Waldenstrom’s macroglobulinemia, or lymphoma.

CXCR4 Mutations in Waldenström Macroglobulinemia as a Potential Therapeutic Target

Concurrent CXCR4 and MYD88 L265P mutations were found to occur in patients with Waldenström macroglobulinemia.

Women who survive breast cancer may have a higher-than-average risk of developing thyroid cancer in

Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenström Macroglobulinemia

In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.

The model stratified patients into 3 risk groups based on median time to disease progression.

Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia

Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Single-Agent Ibrutinib Versus Rituximab-Based Chemoimmunotherapy in Waldenström Macroglobulinemia

No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.

A review published in Blood highlights new approaches that are being investigated to treat PCNSL bas

Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement

According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.

Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively

CXCR4^S338X Clonality Predicts Ibrutinib Outcomes in Waldenström Macroglobulinemia

WM patients with high CXCR4S338X clonality had worse outcomes after ibrutinib therapy compared with patients who had low CXCR4S338X clonality.

More Edema With Bacteriuria in Hereditary Angioedema With Deficiency

Novel Therapies on the Horizon for Waldenström Macroglobulinemia

New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic im

Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia

A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.

Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab

Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.

Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia

The model stratified patients into 3 risk groups based on median time to disease progression.

2019 Year in Review: Waldenström Macroglobulinemia